Following the launch of the #WhatsYourPlan campaign in November 2021, ADI examines the campaign’s successes in its first year.
Alzheimer and dementia associations in the Caribbean are calling for National Dementia Plans to be created and implemented through the #WhatsYourPlan campaign.
Lecanemab is the second Alzheimer’s disease pharmaceutical treatment to come to market since 2003, following the conditional approval of Aduhlem (aducanumab) in June 2022.
A joint letter was submitted in anticipation of the 3rd session of the World Health Organization's Intergovernmental Negotiating Body on 5-7 December.
Eisai presented the results of their confirmatory Phase 3 clinical trial (CLARITY AD) at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, which many are hailing as positive news for the field.
In a press release, Roche confirmed that the Phase 3 GRADUATE studies for gantenerumab did not meet their primary goal of slowing clinical decline in people with early Alzheimer’s disease.
The communiqué calls on the G20 to lead the way in being truly values-driven for global impact and to operate in an environment where there is an agreement on shared values, clarity on unique values across nations, understanding of the values of difference and more.
Results from the LUCIDTY Phase 3 study suggests initial positive results for early and mild to moderate Alzheimer’s Disease
‘Integrating palliative care for older adults’ was written with ADI, The Worldwide Hospice Palliative Care Alliance (WHPCA), SANAD Hospice Lebanon and Hamad Medical Corporation (HMC).
ADI warmly welcomes the positive initial data reported today by Eisai and Biogen on the CLARITY AD global Phase 3 clinical trial of lecanemab.